Evidence map›Paper›PMID 35779013›Full record

ArticleJournal of neuropathology and experimental neurology2022

Apolipoprotein E ε4 Mediates Myelin Breakdown by Targeting Oligodendrocytes in Sporadic Alzheimer Disease.

Gerald Wai-Yeung Cheng, Kingston King-Shi Mok, Sunny Hoi-Sang Yeung, Julia Kofler, Karl Herrup, Kai-Hei Tse

Open access · bronzeAbstract read
In one paragraph

Article in Journal of neuropathology and experimental neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. White Matter Microstructural Alterations Mediate the Association between Polygenic Risk for Alzheimer's Disease and Cognitive Performance in Clinically Asymptomatic Adults.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Emerging Role of Oligodendrocytes Malfunction in the Progression of Alzheimer's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Gerald Wai-Yeung ChengFrom the Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.
Kingston King-Shi MokFrom the Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.
Sunny Hoi-Sang YeungFrom the Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.
Julia KoflerDivision of Neuropathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Karl HerrupDepartment of Neurobiology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Kai-Hei TseFrom the Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR.ORCID 0000-0001-7287-3984
Hong Kong Polytechnic University · HKUniversity of Pittsburgh · US

Funding

TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, JAMES T. · 1985 to 2019
$43.0M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN · 2020 to 2026
$29.4M
Genetic and molecular correlates of white matter pathology in Alzheimers diseaseR01AG069912 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KOFLER, JULIA K · 2021 to 2025
$2.8M
NIA NIH HHS P30 AG066468NIA NIH HHS P50 AG005133NIA NIH HHS R01 AG069912
6 · The paper itself

Abstract

White matter degradation in the frontal lobe is one of the earliest detectable changes in aging and Alzheimer disease. The ε4 allele of apolipoprotein E (APOE4) is strongly associated with such myelin pathology but the underlying cellular mechanisms remain obscure. We hypothesized that, as a lipid transporter, APOE4 directly triggers pathology in the cholesterol-rich myelin sheath independent of AD pathology. To test this, we performed immunohistochemistry on brain tissues from healthy controls, sporadic, and familial Alzheimer disease subjects. While myelin basic protein expression was largely unchanged, in frontal cortex the number of oligodendrocytes (OLs) was significantly reduced in APOE4 brains independent of their Braak stage or NIA-RI criteria. This high vulnerability of OLs was confirmed in humanized APOE3 or APOE4 transgenic mice. A gradual decline of OL numbers was found in the aging brain without associated neuronal loss. Importantly, the application of lipidated human APOE4, but not APOE3, proteins significantly reduced the formation of myelinating OL in primary cell culture derived from Apoe-knockout mice, especially in cholesterol-depleted conditions. Our findings suggest that the disruption of myelination in APOE4 carriers may represent a direct OL pathology, rather than an indirect consequence of amyloid plaque formation or neuronal loss.

Indexed as

Alzheimer DiseaseApolipoprotein E4Myelin SheathOligodendrogliaAmyloid beta-PeptidesAnimalsApolipoprotein E3Apolipoproteins EHumansMiceMice, TransgenicAmyloid beta-PeptidesApoE protein, humanApolipoprotein E3Apolipoprotein E4Apolipoproteins EAlzheimer diseaseAmyloid-independentAPOE4Lipid transportMyelinOligodendrocyte

Identifiers

PMID35779013
PMCPMC9393713
OpenAlexW4283786315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.